1242087-93-9

Basic information

• Product Name: ravidasvir,PPI-668
• Synonyms: ravidasvir,PPI-668;Ravidasvir;Sifuvirtide
• CAS NO: 1242087-93-9
• Molecular Formula: C42H50N8O6
• Molecular Weight: 762.8964
• EINECS: -0
• Mol File: 1242087-93-9.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 1063.5±65.0 °C(Predicted)
• Appearance: /
• Density: 1.284±0.06 g/cm3(Predicted)
• PKA: 11.22±0.46(Predicted)
• CAS DataBase Reference: ravidasvir,PPI-668(CAS DataBase Reference)
• NIST Chemistry Reference: ravidasvir,PPI-668(1242087-93-9)
• EPA Substance Registry System: ravidasvir,PPI-668(1242087-93-9)

Safety Data

• Hazardous Substances Data: 1242087-93-9(Hazardous Substances Data)

Usage

General Description

Ravidasvir and PPI-668 are both antiviral drugs that have shown promise in the treatment of hepatitis C virus (HCV) infections. Ravidasvir is a direct-acting antiviral agent that works by targeting the NS5A protein, which is essential for the replication of the hepatitis C virus. It has been studied in combination with other antiviral drugs and has demonstrated high rates of sustained virologic response in patients with HCV. PPI-668, on the other hand, is a non-nucleoside inhibitor of the viral polymerase and has shown potent activity against a broad range of HCV genotypes. Both of these chemicals represent new and innovative treatment options for patients with HCV, particularly those who have failed previous therapy or who have difficult-to-treat genotypes.

Upstream product

• 1228552-45-1 methyl (S)-1-((S)-2-(6-bromo-1H-benzo[d]imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl-carbamate 
• 181827-47-4 (2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidine-2-carboxylic acid 
• 1228552-50-8 (((S)-3-methyl-1-oxo-1-((S)-2-(6-(4,4,5,5-tetramethyl-1,3,2-dioxolo)ethylpentocycloboran-2-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-1-yl)propan-2-yl)carbamate 
• 59378-82-4 N-(tert-butoxycarbonyl)pyrrolidine-2-carboxaldehyde 
• 1228553-66-9 methyl (S)-3-methyl-1-oxo-1-((S)-2-(5-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-2-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)butan-2-ylcarbamate 
• 1228552-12-2 methyl (S)-1-((S)-2-(5-(6-bromonaphthalen-2-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 1228552-34-8 C₃₈H₄₄N₆O₄ 
• 1208007-67-3 (S)-tert-butyl 2-(6-bromo-1H-benzo[d]imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1575-37-7 4-Bromo-benzene-1,2-diamine 
• 1228633-23-5 C₂₈H₂₈N₆ 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 1228552-26-8 (S)-tert-butyl 2-(5-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-2-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1228551-96-9 (S)-tert-butyl 2-(5-(6-bromonaphthalen-2-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 

Relevant articles and documents

NOVEL BENZIMIDAZOLE DERIVATIVES

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Discovery of ledipasvir (GS-5885): A potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection

A new class of highly potent NS5A inhibitors with an unsymmetric benzimidazole-difluorofluorene-imidazole core and distal [2.2.1]azabicyclic ring system was discovered. Optimization of antiviral potency and pharmacokinetics led to the identification of 39 (ledipasvir, GS-5885). Compound 39 (GT1a replicon EC50 = 31 pM) has an extended plasma half-life of 37-45 h in healthy volunteers and produces a rapid >3 log viral load reduction in monotherapy at oral doses of 3 mg or greater with once-daily dosing in genotype 1a HCV-infected patients. 39 has been shown to be safe and efficacious, with SVR12 rates up to 100% when used in combination with direct-acting antivirals having complementary mechanisms.

BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES

Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, solvates thereof, wherein R and R' are, each independently,-CR1R2R3, aryl, heteroaryl or heteroC4-6cycloalkyl, whereby aryl and heteroaryl may optionally be substituted with 1 or 2 substituents selected from halo and methyl. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.